Skip to main content
. Author manuscript; available in PMC: 2022 Feb 28.
Published in final edited form as: Cancer Lett. 2020 Nov 30;499:99–108. doi: 10.1016/j.canlet.2020.11.041

Figure 4. The activation and memory status of T cells was enhanced following treatment with αCD137 agonist, GVAX and αPD-1.

Figure 4.

Mice were inoculated with 2×105 KPC cells via the hemispleen surgery, treated and sacrificed 14 days after KPC cell inoculation for isolation of tumor-infiltrating immune cells for flow cytometry analysis. Number of (A.) CD4+PD-1+OX40+, (B.) CD4+PD-1+CD137+, (C.) CD8+PD-1+OX40+ and (D.) CD8+PD-1+CD137+ T cells. Numbers of (E.) effector memory T-cells: CD8+CD44+ CD62L−CCR7− and percentages of (F.). effector memory T-cells among CD8+ T cells. Unpaired t tests were done. * p<0.05; ** p<0.01; *** p<0.001. Numbers of T cells were normalized by the total cell counts of the single cell suspension of the livers. Data represents mean ±SEM in one representative experiment (n=3 per treatment group per experiment, repeated twice).